$1.32
2.94% today
Nasdaq, Feb 28, 05:16 pm CET
ISIN
US70465T1079
Symbol
PDSB
Sector
Industry

PDS Biotechnology Corp. Stock price

$1.36
-0.09 6.21% 1M
-1.76 56.41% 6M
-0.27 16.56% YTD
-4.74 77.70% 1Y
-4.62 77.26% 3Y
+0.10 7.94% 5Y
-257.44 99.47% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
-0.18 11.69%
ISIN
US70465T1079
Symbol
PDSB
Sector
Industry

Key metrics

Market capitalization $50.88m
Enterprise Value $25.80m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 2.28
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-39.37m
Free Cash Flow (TTM) Free Cash Flow $-35.28m
Cash position $49.75m
EPS (TTM) EPS $-1.17
P/E forward negative
Short interest 11.08%
Show more

Is PDS Biotechnology Corp. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

PDS Biotechnology Corp. Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a PDS Biotechnology Corp. forecast:

4x Buy
100%

Analyst Opinions

4 Analysts have issued a PDS Biotechnology Corp. forecast:

Buy
100%

Financial data from PDS Biotechnology Corp.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 0.06 0.06
67% 67%
-
-0.06 -0.06
67% 67%
-
- Selling and Administrative Expenses 14 14
6% 6%
-
- Research and Development Expense 26 26
30% 30%
-
-39 -39
23% 23%
-
- Depreciation and Amortization 0.06 0.06
67% 67%
-
EBIT (Operating Income) EBIT -39 -39
23% 23%
-
Net Profit -41 -41
21% 21%
-

In millions USD.

Don't miss a Thing! We will send you all news about PDS Biotechnology Corp. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

PDS Biotechnology Corp. Stock News

Positive
Proactive Investors
about 8 hours ago
EMV Capital plc (AIM: EMVC) portfolio company PDS Biotechnology Corporation (Nasdaq: PDSB) has raised $11 million, through an equity funding. PDS, which is focussed on immunotherapies, sold around 7.33 million new shares in a direct offer, plus warrants which (if exercised) will bring in another $11 million.
Neutral
GlobeNewsWire
one day ago
PRINCETON, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced it has entered into securities purchase agreements with new and existing healthcare focused institutional investors as well as participation fr...
Neutral
GlobeNewsWire
2 days ago
Median Overall Survival (mOS) of 42.4 months in immune checkpoint inhibitor naïve patients; Historical published result is 7-12 months Continued survival in the cohort of HPV16-positive immune checkpoint inhibitor naïve patients - mOS not yet reached Median OS of 17 months in HPV16-positive immune checkpoint inhibitor resistant patients; Historically published result is 3-4 months Significant t...
More PDS Biotechnology Corp. News

Company Profile

PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. The company was founded by Frank K. Bedu-Addo on March 15, 2019 and is headquartered in Princeton, NJ.

Head office United States
CEO Frank Bedu-Addo
Employees 25
Founded 2005
Website www.pdsbiotech.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today